Analyst: Eli Lilly considers Alzheimer's submission after phase II

Eli Lilly is so enthusiastic about its potential Alzheimer's treatment donanemab that the firm is ready to submit the drug for evaluation on the basis of data coming from two phase II trials.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030

Drug candidate donanemab might potentially become the second Alzheimer's drug to be submitted to the US Food and Drug Administration within a short time span.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading